Welcome to our dedicated page for 23Andme Holding Co SEC filings (Ticker: ME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company built on millions of DNA samples can get complicated fast. 23andMe’s filings cover subscription revenue swings, R&D for gene-based therapies, and rigorous privacy safeguards—topics that turn a routine 10-K into a dense read. If you’ve ever wondered “How do I find 23andMe SEC filings explained simply?” or needed 23andMe insider trading Form 4 transactions in real time, you know the challenge.
Stock Titan removes the guesswork. Our AI combs every page the moment a document hits EDGAR, highlights the exact sections on data-privacy risk, breaks down non-cash stock-based compensation, and flags executive stock sales with 23andMe Form 4 insider transactions real-time alerts. Whether it’s the 23andMe quarterly earnings report 10-Q filing or an 8-K announcing a new research partnership, you’ll see concise explanations, plain-language tables, and trend charts in seconds.
Here’s what you can do inside one dashboard:
- Compare cash burn and R&D spend across each 23andMe earnings report filing analysis
- Monitor 23andMe executive stock transactions Form 4 before material events
- Read a 23andMe annual report 10-K simplified summary that spotlights subscription growth and privacy litigation
- Dive into the latest 23andMe 8-K material events explained by our models
- Locate board pay details through the 23andMe proxy statement executive compensation section
Stop searching multiple sources. Stock Titan’s AI-powered summaries, expert annotations, and real-time filing updates turn complex genomic disclosures into actionable insight so you can focus on decisions, not document hunts.
23andMe Holding Co. (ME) receives Bankruptcy Court approval to sell substantially all assets. On 27 June 2025, the U.S. Bankruptcy Court for the Eastern District of Missouri entered an order authorizing the Debtors to consummate the previously announced Asset Purchase Agreement with TTAM Research Institute, a California non-profit affiliated with co-founder Anne Wojcicki.
Transaction terms: TTAM will purchase virtually all assets—excluding Lemonaid Health’s tele-health operations—for $305.0 million in cash and will assume specified liabilities. TTAM will also act as stalking-horse sponsor to acquire the excluded Lemonaid business for $2.5 million.
Key timeline:
- Chapter 11 petitions filed: 23 March 2025
- Asset Purchase Agreement executed: 13 June 2025
- Court approval of sale: 27 June 2025
- Press release issued: 30 June 2025 (Exhibit 99.1)
The Company reiterates that trading in Class A common stock is highly speculative; market prices may not correspond to any ultimate recovery. No pro-forma financials or creditor recovery estimates were included in this Form 8-K. Stakeholders can access additional documents via Kroll’s restructuring website or hotline.
FAQ
What is the current stock price of 23Andme Holding Co (ME)?
What is the market cap of 23Andme Holding Co (ME)?
